RRX-001 is under clinical development by EpicentRx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RRX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RRX-001 overview

RRX-001 is under development for the treatment of advanced solid tumors, metastatic colorectal cancer, brain metastases, small-cell lung cancer, Parkinson's disease, relapsed and refractory multiple myeloma, non-small cell lung cancer, radiation induced oral mucositis, small cell lung cancer, epithelial ovarian cancer, high grade neuroendocrine tumors, lymphoma, cerebral malaria, newly diagnosed high-grade glioma, including anaplastic glioma, glioblastoma, metastatic castration resistant neuroendocrine prostate cancer (NEPC), gliosarcoma, liver cancer, acute radiation syndrome, inflammation and recurrent or progressive malignant solid and central nervous system tumors. It is administered through intravenous, subcutaneous route and as a hepatic artery infusion. It is a prototypic dinitroazetidine molecule. The drug candidate has dual mode of action by acting as antivascular and anti-tumor agent. It acts by targetting NACHT LRR and PYD domains containing protein 3.

It was also under development for  advanced cholangiocarcinoma, elapsed Multiple myeloma,cerebral (fatal) malaria, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, refractory multiple myeloma and lymphoma . The drug candidate is being developed based on CyNRGY platform.

EpicentRx overview

EpicentRx, formerly RadioRx, is a biopharmaceutical company that discovers and develops therapies for cancer and chronic diseases. The company utilizes CyNRGY platform to develop RRx-001, a NLRP3 inhibitor to treat small cell lung cancer, neurodegenerative diseases, liver and blood cancer; and eLoop administration device to optimize delivery of Intravenous administered treatments. It is also investigating AdAPT-001, an oncolytic virus that carries transformative growth factor beta trap transgene to neutralize TGF-ß within the infected tumor. EpicentRx works in collaboration with Texas Children’s Cancer Center to examine safety and benefits of RRx-001 in patients with malignant solid and central nervous tumors. EpicentRx is headquartered in San Diego, California, the US.

For a complete picture of RRX-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.